MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $125.90M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.72M
Average 0.98M
MGNX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
MacroGenics, Inc.NASDAQ: MGNX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$3.34M, compared with $1.59M a year earlier. Trailing-twelve-month other income / expenses was -$7.37M.
Context
- Other income / expenses amounted to 1.6% of revenue in FY2025, down 28.4 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$3.34M or moves back toward the trailing-twelve-month quarterly average of -$1.84M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (2.45M) USD
- Year-over-year change
- -105.5%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.45M) | -105.5% |
| FY2024 | 2024-12-31 | 44.56M | -72.0% |
| FY2023 | 2023-12-31 | 159.19M | +9489.5% |
| FY2022 | 2022-12-31 | 1.66M | +144.1% |
| FY2021 | 2021-12-31 | 680K | — |
Other Income / Expenses vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -116.5% is the 10th highest of 11, against a peer median of -40.2%.
- Other income / expenses amounts to 4.7% of revenue for MGNX, versus a peer median of 915.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $146.07M USD | +1533.0% | +213.5% | — | |
| LTM Mar 2026 | $23.57M USD | -26.4% | +162.8% | 330.9% | |
| LTM Mar 2026 | $21.47M USD | +277.4% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $6.9M USD | -92.4% | +251.1% | — |
| LTM Mar 2026 | $3.29M USD | -17.6% | +87.2% | — | |
| FY2025 | $2.79M USD | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | $2.79M USD | -35.2% | +24.9% | 279.0% | |
| LTM Mar 2026 | $869.27K USD | -45.2% | — | 10.9% | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -$7.37M USD | -116.5% | — | 4.7% | |
| LTM Mar 2026 | -$12.7M USD | -1019.6% | — | 9474.6% | |
| Peer median (excluding MGNX) | — | -40.2% | +87.2% | 915.8% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| Weighted Avg Shares | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Weighted Avg Shares (Diluted) | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.